(Total Views: 41)
Posted On: 08/21/2025 12:06:48 PM
Post# of 402
$ADTX Recent News : Aditxt’s Subsidiary, Pearsanta, Inc. Engages Spartan Capital as Lead Underwriter for its Planned IPO Intending to Drive Clinical Validation and Commercial Rollout of Its Mitomic™ Platform Technology for Early Detection of Cancers and Other Diseases
Planned IPO Aligns with Aditxt’s Acquire, Build and Capitalize (ABC) Monetization Framework
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"
, a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc., (“Pearsanta”) has engaged Spartan Capital Securities, LLC (“Spartan”) as lead underwriter for its planned Initial Public Offering (”IPO”). This marks an important milestone in Aditxt’s Acquire, Build, and Capitalize (“ABC”) strategy, which is designed to accelerate the growth of innovative health companies.
Spartan will serve as Pearsanta’s exclusive financial advisor and bookrunner for the offering. The proposed IPO is intended to support the clinical validation, and commercial rollout of Pearsanta’s innovative tests designed for early detection of cancers and other diseases, powered by its Mitomic™ mitochondrial DNA platform technology, and CLIA-certified, CAP-accredited laboratory infrastructure.
https://www.businesswire.com/news/home/202507...r-Diseases
Planned IPO Aligns with Aditxt’s Acquire, Build and Capitalize (ABC) Monetization Framework
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"
, a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc., (“Pearsanta”) has engaged Spartan Capital Securities, LLC (“Spartan”) as lead underwriter for its planned Initial Public Offering (”IPO”). This marks an important milestone in Aditxt’s Acquire, Build, and Capitalize (“ABC”) strategy, which is designed to accelerate the growth of innovative health companies. Spartan will serve as Pearsanta’s exclusive financial advisor and bookrunner for the offering. The proposed IPO is intended to support the clinical validation, and commercial rollout of Pearsanta’s innovative tests designed for early detection of cancers and other diseases, powered by its Mitomic™ mitochondrial DNA platform technology, and CLIA-certified, CAP-accredited laboratory infrastructure.
https://www.businesswire.com/news/home/202507...r-Diseases
(0)
(0)
